Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Multi-antigen immunization using IgG binding domain ZZ as carrier.

Yixian Zhao1, Yair Benita, Martin Lok

  • 1Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Sorbonnelaan 16, 3584 CA Utrecht, The Netherlands. y.zhao@pharm.uu.nl

Vaccine
|July 21, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Boosting Vaccine Research: The 16-Year Journey of TRANSVAC Vaccine Infrastructure.

Vaccines·2025
Same author

Stability of Protein Pharmaceuticals: Recent Advances.

Pharmaceutical research·2024
Same author

The Carnitine Palmitoyl-Transferase 2 Cascade Hypothesis for Alzheimer's Disease.

Journal of Alzheimer's disease : JAD·2023
Same author

Outer membrane vesicle-based intranasal vaccines.

Current opinion in immunology·2023
Same author

Lipid A heterogeneity and its role in the host interactions with pathogenic and commensal bacteria.

microLife·2023
Same author

The Storage and In-Use Stability of mRNA Vaccines and Therapeutics: Not A Cold Case.

Journal of pharmaceutical sciences·2022

This study presents a new method for testing multiple vaccine candidates simultaneously. Combining ZZ-fusion antigens with QuilA adjuvant significantly enhances immune response, improving vaccine discovery.

Area of Science:

  • Vaccinology
  • Immunology
  • Protein Engineering

Background:

  • Developing effective vaccines requires testing numerous candidates.
  • Neisseria meningitidis group B poses a significant public health challenge.
  • Recombinant protein expression is a key technology in vaccine development.

Purpose of the Study:

  • To develop a high-throughput method for evaluating multiple vaccine candidates in parallel.
  • To assess the immunogenicity of recombinant antigens derived from Neisseria meningitidis group B.
  • To compare the efficacy of ZZ-fusion and His-tag fusion proteins as vaccine candidates.

Main Methods:

  • Cloning and expression of Neisseria meningitidis group B antigens as ZZ-fusion or His-tag recombinant proteins.
  • Immunization of mice with mixtures of 22 antigens, with and without QuilA adjuvant.

Related Experiment Videos

  • Analysis of antibody response and dose-dependency to assess immunogenicity.

    • Main Results:

    • A mixture of 22 ZZ-fusion antigens with QuilA adjuvant induced a significantly enhanced immune response in mice.
    • The ZZ-fusion antigens/QuilA combination elicited a higher number of antibody responses compared to His-tagged antigens.
    • A substantially lower antigen dose was required to achieve an immune response with ZZ-fusion antigens and QuilA.

    Conclusions:

    • The ZZ-fusion antigens combined with QuilA adjuvant represent a potent strategy for enhancing immunogenicity.
    • This approach serves as an effective high-throughput discovery tool for identifying novel vaccine candidates.
    • The findings pave the way for more efficient development of vaccines against Neisseria meningitidis group B and potentially other pathogens.